mirabegron
Pharmaranks rates Mirabegron 3.4/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Mirabegron is a beta3-adrenergic agonist used to treat Overactive Urinary Bladder, Urge Urinary Incontinence.
Beta3-Adrenergic Agonist · by Aurobindo Pharma Ltd
Generic of Myrbetriq
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Mirabegron
- Drug class
- Beta3-Adrenergic Agonist
- Form
- Tablet, extended release
- Strength
- Mirabegron 50MG
- Type
- Prescription (Rx)
- Brand or generic
- Generic
- Manufacturer
- Aurobindo Pharma Ltd
- Half-life
- about 50 hours (how long it stays in your system)
- What the pharmacy pays
- ~$288.81 for 30 — not your price
- FDA application
- ANDA209413
- Availability
- Discontinued (per FDA)
Storing Mirabegron, and how long it keeps
Quoted from this product’s own FDA label. Storage belongs to the product and its device, not to the drug in general — a pen and a tablet of the same medicine are kept completely differently.
- “Discard the unused portion after 28 days.”
- “Discard the unused portion after 28 days [see How Supplied/Storage and Handling ( 16.”
How long does Mirabegron stay in your body?
The elimination half-life of mirabegron is about 50 hours — the time it takes the body to clear about half of it. As a rule of thumb, a medicine is mostly gone after roughly 4 to 5 half-lives, though this varies from person to person with age and kidney or liver function. The FDA label gives a terminal elimination half-life of roughly 50 hours for adults taking the extended-release tablets (all US oral mirabegron products are extended-release; the label reports no separate immediate-release value — IR tablets appear only in drug-interaction studies). Because of that long half-life, blood levels keep rising for about a week, and the label states steady state is reached within 7 days of once-daily dosing, with steady-state exposure roughly double that of a single dose. No active metabolite outlasts the parent: the two major circulating metabolites are phase-2 glucuronides (16% and 11% of total exposure) that the label describes as not pharmacologically active at the beta-3 adrenergic receptor, so mirabegron itself is the main active compound. Age does not change it much — the label reports Cmax and AUC in volunteers 65 and older were similar to those in adults 18 to 45. Reduced kidney or liver function raises how much drug is in the body rather than a stated change in half-life: AUC was 31%, 66%, and 118% higher in mild, moderate, and severe renal impairment, and 19% and 65% higher in mild and moderate (Child-Pugh A and B) hepatic impairment; mirabegron has not been studied in end-stage renal disease, dialysis, or severe (Child-Pugh C) hepatic impairment. Children are different: in pediatric patients treated for neurogenic detrusor overactivity with the tablets or granules, the mean terminal half-life is about 26 to 31 hours.
This is general information, not medical advice. It doesn’t tell you when a drug test would read negative (tests detect substances for different, often longer, windows) or when it’s safe to take another dose — ask your pharmacist or prescriber. Source: MYRBETRIQ (mirabegron) extended-release tablets and granules — FDA prescribing information, section 12.3 Pharmacokinetics.
Drug class
May treat (source: NIH RxClass)
See how Mirabegron ranks — best-rated beta3-adrenergic agonist for:
Dosage forms
Tablet, extended release
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Mirabegron treat?
- Mirabegron (Mirabegron) may be used to treat overactive urinary bladder, urge urinary incontinence, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Mirabegron rated?
- pharmaranks gives Mirabegron a composite score of 3.4 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- How much does Mirabegron cost?
- Nobody can tell you what you will pay — your price is set by your insurer's formulary, your deductible and the pharmacy's markup, and none of those are published. What IS published is what the pharmacy paid to acquire it: about $288.81 for 30, per the CMS NADAC survey. Treat that as the floor, not the quote — ask the pharmacist for the cash price as well as your copay, because for cheap generics the cash price often wins.
- Is there a coupon or discount for Mirabegron?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Mirabegron. To pay less, Mirabegron is already a generic — usually the lowest-cost version — so the main levers are comparing cash prices between pharmacies and using a pharmacy discount-card service. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Mirabegron?
- Mirabegron is marketed by Aurobindo Pharma Ltd. You can see Aurobindo Pharma Ltd's full profile, rating, and other products on pharmaranks.
- Is Mirabegron a brand-name or generic drug?
- Mirabegron is a generic medication; its active ingredient is Mirabegron. Generics contain the same active ingredient as the brand-name original and are usually lower cost.
- Is Mirabegron available over the counter?
- No. Mirabegron is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Mirabegron come in?
- Mirabegron is currently marketed as tablet, extended release, per the FDA's National Drug Code Directory.
- What class of drug is Mirabegron?
- Mirabegron is classified as beta3-adrenergic agonist, per the FDA's Established Pharmacologic Class.
- Is Mirabegron FDA-registered?
- Mirabegron is on record with the U.S. FDA under application number ANDA209413. You can verify this on its official FDA label.
- Has Mirabegron been recalled by the FDA?
- Mirabegron has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Mirabegron safe?
- There's no single safe-or-not verdict. pharmaranks gives Mirabegron a recall-safety score of 68/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Mirabegron head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
mirabegron
68/100